title: Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects.
abstract: Matrix metalloproteinases (MMPs) are involved in the regulation of the extracellular matrix (ECM) of the myocardium and thus the pathogenesis of vascular and cardiac hypertrophy. In this study, we investigated contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy (LVH) and diastolic dysfunction in hypertensive subjects. Hypertensive patients with (n = 27) and without LVH (n = 23) were included. All participants underwent a complete transthoracic echocardiographic examination, including recordings of the mitral annular early, late, systolic and diastolic velocities by Doppler imaging. Plasma concentrations of MMP-3 and MMP-9 were determined by the one-step sandwich enzyme immunoassay method. Plasma MMP-3 and MMP-9 concentrations were significantly higher in patients with LVH than those without LVH (2.4 +/- 1.2 vs 1.5 +/- 0.7 ng/ml, p = 0.006 and 5.2 +/- 2.8 vs 3.3 +/- 1.7 ng/ml, p = 0.003, respectively). MMP-3 and MMP-9 levels were also correlated with left ventricular posterior wall thickness and Doppler indices of diastolic dysfunction. Our findings have suggested that increased MMP levels may contribute to LVH and left ventricular diastolic dysfunction. Therefore, treatment of hypertension with MMP lowering drugs, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers, may have favorable effects on LVH and left ventricular diastolic dysfunction.
authors.affiliation: Department of Cardiology, Kosuyolu Heart Education and Research Hospital, Istanbul, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Saglam
authors.forename: Osman
authors.initials: O
authors.lastname: Karakaya
authors.forename: Ali Metin
authors.initials: AM
authors.lastname: Esen
authors.forename: Irfan
authors.initials: I
authors.lastname: Barutcu
authors.forename: Serkan
authors.initials: S
authors.lastname: Dogan
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Karavelioglu
authors.forename: Hekim
authors.initials: H
authors.lastname: Karapinar
authors.forename: Taylan
authors.initials: T
authors.lastname: Akgun
authors.forename: Ozlem
authors.initials: O
authors.lastname: Esen
authors.forename: Nihal
authors.initials: N
authors.lastname: Ozdemir
authors.forename: Sembol
authors.initials: S
authors.lastname: Turkmen
authors.forename: Cihangir
authors.initials: C
authors.lastname: Kaymaz
mesh_terms: D000368:Aged; D003971:Diastole; D004452:Echocardiography; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications*; D017379:Hypertrophy, Left Ventricular / Q000209:etiology*; D008297:Male; D020782:Matrix Metalloproteinases / Q000097:blood*; D008875:Middle Aged; D011480:Protease Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D012307:Risk Factors; D019714:Tissue Inhibitor of Metalloproteinases / Q000009:adverse effects*; D018754:Ventricular Dysfunction / Q000209:etiology*
chemical_list: D011480:Protease Inhibitors; D019714:Tissue Inhibitor of Metalloproteinases; D020782:Matrix Metalloproteinases